Condition
Hemangiopericytoma
Total Trials
5
Recruiting
2
Active
2
Completed
2
Success Rate
66.7%-20% vs avg
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 47/100
Termination Rate
20.0%
1 terminated out of 5 trials
Success Rate
66.7%
-19.8% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
100%
2 of 2 completed with results
Key Signals
2 with results67% success
Data Visualizations
Phase Distribution
3Total
P 1 (1)
P 2 (2)
Trial Status
Completed2
Recruiting2
Terminated1
Trial Success Rate
66.7%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT05259605Recruiting
Observational Study for Assessing Treatment and Outcome of Patients With Primary Brain Tumours Using cIMPACT-NOW and 2021 WHO Classification
NCT03016091Phase 2Terminated
A Trial of Pembrolizumab for Refractory Atypical and Anaplastic Meningioma
NCT04648462Recruiting
Proton Therapy Research Infrastructure- ProTRAIT- Neuro-oncology
NCT01117844Phase 1Completed
Proton Radiation For Meningiomas and Hemangiopericytomas
NCT00464620Phase 2Completed
Trial of Dasatinib in Advanced Sarcomas
Showing all 5 trials